Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals

We are focused on developing novel gastrointestinal therapies that serve the unmet needs of patients and create value for our shareholders.

Learn more about Synergy

Our Team

We have GI expertise and the commitment to develop and bring to market treatments that address the unmet needs of patients.

Learn more about Synergy's team


Plecanatide is our lead uroguanylin analog currently in late-stage clinical development for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

Learn more about plecanatide

Our Approach

Our proprietary GI platform is based on uroguanylin– a naturally occurring human peptide that plays a key role in regulating normal digestive activity. We have discovered and are developing two unique analogs of uroguanylin, plecanatide and dolcanatide (formerly SP-333), as novel therapies for the treatment of GI diseases and disorders.

Learn more about Synergy's Approach

Our Pipeline

Synergy’s Proprietary Platform

Plecanatide is our first generation uroguanylin analog in late-stage clinical development for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Dolcanatide is our next generation uroguanylin analog that has successfully completed a phase 2 study in patients with opioid induced constipation (OIC) and is currently being evaluated for the treatment of ulcerative colitis (UC).

Learn more about our pipeline
Compound Indication Phase 1 Phase 2 Phase 3 Market
Go to News & Media

Latest News & Events

Go To Investor Relations

Investor Relations


Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders.

Recent Documents

Market Cap